Company Overview
About Catena Biosciences
Catena Biosciences is a United States-based biotechnology company — backed by Y Combinator (W21) with $9.1 million in total funding including a $2.35 million seed round in May 2024 from LongeVC, CA Innovation Fund, Civilization Ventures, Pioneer Fund, Freeflow Ventures, Caffeinated Capital, and BrightEdge Capital, plus NIH SBIR grants — developing next-generation protein conjugation technology that enables the rapid, selective attachment of functional payloads (drugs, labels, polymers, other proteins) to therapeutic proteins using natural amino acids as conjugation handles, generating $750,000 in annual revenue as of June 2025 and serving pharmaceutical companies and researchers developing antibody-drug conjugates (ADCs), bispecific antibodies, vaccine adjuvants, and next-generation protein therapeutics for autoimmune disorders, oncology, and infectious disease.
Business Model & Competitive Advantage
Catena Biosciences' Multi Payload Conjugate (MPC) platform addresses a fundamental limitation in antibody-drug conjugate development: conventional protein conjugation methods (NHS ester chemistry, maleimide chemistry) attach drug payloads to antibodies at non-specific sites (random lysine or cysteine residues throughout the antibody) — creating heterogeneous conjugates with variable drug-to-antibody ratios (DAR) that affect pharmacokinetics, efficacy, and safety. The FDA-approved ADC Kadcyla (ado-trastuzumab emtansine) exemplifies the heterogeneity problem: different antibody molecules in the same batch carry 0, 2, 4, or 8 drug molecules, creating a mixture with variable potency and off-target toxicity. Catena's site-specific conjugation chemistry (using engineered unnatural amino acid handles or novel selective chemistry at specific natural amino acid sites) enables pharmaceutical researchers to produce homogeneous conjugates with defined, controlled conjugation sites and stoichiometries — improving the ADC therapeutic window and manufacturing consistency critical for clinical development.
Competitive Landscape 2025–2026
In 2025, Catena Biosciences competes in the protein conjugation technology, ADC development tools, and biologics manufacturing services market with Ajinomoto (ADC site-specific conjugation services), Innate Pharma (site-specific conjugation technology platform, acquired by AstraZeneca), and Abzena (ADC CDMO with conjugation services, $150M raised) for pharmaceutical company ADC and protein therapeutic conjugation service adoption. The ADC market has become one of oncology's hottest drug development categories — 14 FDA-approved ADCs by 2025 and 100+ in clinical development — creating growing demand for conjugation services and technology licenses that improve ADC development efficiency. NIH SBIR grant funding validates Catena's scientific approach and provides non-dilutive capital for platform development. Caffeinated Capital's biotech investment focus and Amgen's participation reflect therapeutic protein development industry validation. The 2025 strategy focuses on growing the ADC development service revenue from oncology biotech clients, licensing the MPC platform to large pharmaceutical companies for internal ADC programs, and building the GMP-compatible conjugation manufacturing for clinical-stage ADC customers.
Recent Activity
View all →Key Differentiators
Emerging Innovator
Catena Biosciences is an emerging player bringing innovative solutions to the Healthcare market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Epic Systems
Epic Systems Corporation was founded in 1979 by Judith Faulkner and is headquartered in Verona, Wisconsin, remaining privately held with Faulkner as majority owner. The company develops large-scale el
athenahealth
athenahealth is a cloud-based electronic health records (EHR), medical billing, and practice management company founded in 1997 and headquartered in Watertown, Massachusetts. The company was built on
Oracle Health
Oracle Health is the healthcare technology business unit of Oracle Corporation (NYSE: ORCL) — providing electronic health records (EHR), clinical workflow management, health information exchange, reve
Pfizer
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The compan
Moderna
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stép
Amgen
Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologic
Compare Catena Biosciences with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Catena Biosciences? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Catena Biosciences Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Catena Biosciences vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →